
Hikma Pharmaceuticals PLC
LSE:HIK


to continue HIK research
to continue HIK research
You've reached your weekly stock limit.
Sign UpHikma Pharmaceuticals PLC?
US |
![]() |
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
US |
![]() |
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
US |
![]() |
Bank of America Corp
NYSE:BAC
|
Banking
|
US |
![]() |
Mastercard Inc
NYSE:MA
|
Technology
|
US |
![]() |
UnitedHealth Group Inc
NYSE:UNH
|
Health Care
|
US |
![]() |
Exxon Mobil Corp
NYSE:XOM
|
Energy
|
US |
![]() |
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
US |
![]() |
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
US |
![]() |
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
US |
![]() |
Visa Inc
NYSE:V
|
Technology
|
CN |
![]() |
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
US |
![]() |
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
US |
![]() |
Coca-Cola Co
NYSE:KO
|
Beverages
|
US |
![]() |
Walmart Inc
NYSE:WMT
|
Retail
|
US |
![]() |
Verizon Communications Inc
NYSE:VZ
|
Telecommunication
|
US |
![]() |
Chevron Corp
NYSE:CVX
|
Energy
|
We'll email you a reminder when the closing price reaches USD.
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.

Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
52 Week Range |
1 772
2 340
|
Price Target |
|
We'll email you a reminder when the closing price reaches GBX.
Choose the stock you wish to monitor with a price alert.
![]() |
Johnson & Johnson
NYSE:JNJ
|
US |
![]() |
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
![]() |
Bank of America Corp
NYSE:BAC
|
US |
![]() |
Mastercard Inc
NYSE:MA
|
US |
![]() |
UnitedHealth Group Inc
NYSE:UNH
|
US |
![]() |
Exxon Mobil Corp
NYSE:XOM
|
US |
![]() |
Pfizer Inc
NYSE:PFE
|
US |
![]() |
Palantir Technologies Inc
NYSE:PLTR
|
US |
![]() |
Nike Inc
NYSE:NKE
|
US |
![]() |
Visa Inc
NYSE:V
|
US |
![]() |
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
![]() |
JPMorgan Chase & Co
NYSE:JPM
|
US |
![]() |
Coca-Cola Co
NYSE:KO
|
US |
![]() |
Walmart Inc
NYSE:WMT
|
US |
![]() |
Verizon Communications Inc
NYSE:VZ
|
US |
![]() |
Chevron Corp
NYSE:CVX
|
US |
This alert will be permanently deleted.

What unique competitive advantages
does Hikma Pharmaceuticals PLC hold over its rivals?
What risks and challenges
does Hikma Pharmaceuticals PLC face in the near future?
Is it considered overvalued or undervalued
based on the latest financial data?
Provide an overview of the primary business activities
of Hikma Pharmaceuticals PLC.
Provide an overview of the primary business activities
of Hikma Pharmaceuticals PLC.
What unique competitive advantages
does Hikma Pharmaceuticals PLC hold over its rivals?
What risks and challenges
does Hikma Pharmaceuticals PLC face in the near future?
Has there been any significant insider trading activity
in Hikma Pharmaceuticals PLC recently?
Summarize the latest earnings call
of Hikma Pharmaceuticals PLC.
Is it considered overvalued or undervalued
based on the latest financial data?
Show all valuation multiples
for Hikma Pharmaceuticals PLC.
Provide P/S
for Hikma Pharmaceuticals PLC.
Provide P/E
for Hikma Pharmaceuticals PLC.
Provide P/OCF
for Hikma Pharmaceuticals PLC.
Provide P/FCFE
for Hikma Pharmaceuticals PLC.
Provide P/B
for Hikma Pharmaceuticals PLC.
Provide EV/S
for Hikma Pharmaceuticals PLC.
Provide EV/GP
for Hikma Pharmaceuticals PLC.
Provide EV/EBITDA
for Hikma Pharmaceuticals PLC.
Provide EV/EBIT
for Hikma Pharmaceuticals PLC.
Provide EV/OCF
for Hikma Pharmaceuticals PLC.
Provide EV/FCFF
for Hikma Pharmaceuticals PLC.
Provide EV/IC
for Hikma Pharmaceuticals PLC.
Show me price targets
for Hikma Pharmaceuticals PLC made by professional analysts.
What are the Revenue projections
for Hikma Pharmaceuticals PLC?
How accurate were the past Revenue estimates
for Hikma Pharmaceuticals PLC?
What are the Net Income projections
for Hikma Pharmaceuticals PLC?
How accurate were the past Net Income estimates
for Hikma Pharmaceuticals PLC?
What are the EPS projections
for Hikma Pharmaceuticals PLC?
How accurate were the past EPS estimates
for Hikma Pharmaceuticals PLC?
What are the EBIT projections
for Hikma Pharmaceuticals PLC?
How accurate were the past EBIT estimates
for Hikma Pharmaceuticals PLC?
Compare the revenue forecasts
for Hikma Pharmaceuticals PLC with those of its competitors based on recent analyst estimates.
Compare the intrinsic valuations
of Hikma Pharmaceuticals PLC and its key competitors using the latest financial data.
Compare historical revenue growth rates
of Hikma Pharmaceuticals PLC against its competitors.
Analyze the profit margins
(gross, operating, and net) of Hikma Pharmaceuticals PLC compared to its peers.
Compare the P/E ratios
of Hikma Pharmaceuticals PLC against its peers.
Discuss the investment returns and shareholder value creation
comparing Hikma Pharmaceuticals PLC with its peers.
Analyze the financial leverage
of Hikma Pharmaceuticals PLC compared to its main competitors.
Show all profitability ratios
for Hikma Pharmaceuticals PLC.
Provide ROE
for Hikma Pharmaceuticals PLC.
Provide ROA
for Hikma Pharmaceuticals PLC.
Provide ROIC
for Hikma Pharmaceuticals PLC.
Provide ROCE
for Hikma Pharmaceuticals PLC.
Provide Gross Margin
for Hikma Pharmaceuticals PLC.
Provide Operating Margin
for Hikma Pharmaceuticals PLC.
Provide Net Margin
for Hikma Pharmaceuticals PLC.
Provide FCF Margin
for Hikma Pharmaceuticals PLC.
Show all solvency ratios
for Hikma Pharmaceuticals PLC.
Provide D/E Ratio
for Hikma Pharmaceuticals PLC.
Provide D/A Ratio
for Hikma Pharmaceuticals PLC.
Provide Interest Coverage Ratio
for Hikma Pharmaceuticals PLC.
Provide Altman Z-Score Ratio
for Hikma Pharmaceuticals PLC.
Provide Quick Ratio
for Hikma Pharmaceuticals PLC.
Provide Current Ratio
for Hikma Pharmaceuticals PLC.
Provide Cash Ratio
for Hikma Pharmaceuticals PLC.
What is the historical Revenue growth
over the last 5 years for Hikma Pharmaceuticals PLC?
What is the historical Net Income growth
over the last 5 years for Hikma Pharmaceuticals PLC?
What is the current Free Cash Flow
of Hikma Pharmaceuticals PLC?
Discuss the annual earnings per share (EPS)
trend over the past five years for Hikma Pharmaceuticals PLC.
EV/EBITDA
Enterprise Value to EBITDA
Enterprise Value to EBITDA (EV/EBITDA) ratio is a valuation multiple that compares the value of a company, debt included, to the company’s cash earnings less non-cash expenses. EBITDA can be misleading at times, especially for companies that are highly capital intensive.
Market Cap | EV/EBITDA | ||||
---|---|---|---|---|---|
UK |
![]() |
Hikma Pharmaceuticals PLC
LSE:HIK
|
4.5B GBP | 65.6 | |
US |
![]() |
Eli Lilly and Co
NYSE:LLY
|
753.1B USD | 36.4 |
|
UK |
![]() |
Dechra Pharmaceuticals PLC
LSE:DPH
|
440.4B GBP | 3 846.3 |
|
US |
![]() |
Johnson & Johnson
NYSE:JNJ
|
368B USD | 12.3 |
|
DK |
![]() |
Novo Nordisk A/S
CSE:NOVO B
|
1.9T DKK | 12.8 |
|
CH |
![]() |
Roche Holding AG
SIX:ROG
|
206.3B CHF | 9.4 |
|
CH |
![]() |
Novartis AG
SIX:NOVN
|
186.1B CHF | 10.6 |
|
UK |
![]() |
AstraZeneca PLC
LSE:AZN
|
159.1B GBP | 130.6 |
|
US |
![]() |
Merck & Co Inc
NYSE:MRK
|
200.5B USD | 8.6 |
|
IE |
E
|
Endo International PLC
LSE:0Y5F
|
163.5B USD | 261.3 |
|
US |
![]() |
Pfizer Inc
NYSE:PFE
|
137.9B USD | 7.5 |
|
EBITDA Growth | EV/EBITDA to Growth | |||||
---|---|---|---|---|---|---|
UK |
![]() |
Hikma Pharmaceuticals PLC
LSE:HIK
|
Average EV/EBITDA:
400.1
65.6
|
9%
|
7.3 | |
US |
![]() |
Eli Lilly and Co
NYSE:LLY
|
36.4
|
30%
|
1.2 |
|
UK |
![]() |
Dechra Pharmaceuticals PLC
LSE:DPH
|
3 846.3
|
36%
|
106.8 |
|
US |
![]() |
Johnson & Johnson
NYSE:JNJ
|
12.3
|
7%
|
1.8 |
|
DK |
![]() |
Novo Nordisk A/S
CSE:NOVO B
|
12.8
|
13%
|
1 |
|
CH |
![]() |
Roche Holding AG
SIX:ROG
|
9.4
|
5%
|
1.9 |
|
CH |
![]() |
Novartis AG
SIX:NOVN
|
10.6
|
5%
|
2.1 |
|
UK |
![]() |
AstraZeneca PLC
LSE:AZN
|
130.6
|
10%
|
13.1 |
|
US |
![]() |
Merck & Co Inc
NYSE:MRK
|
8.6
|
8%
|
1.1 |
|
IE |
E
|
Endo International PLC
LSE:0Y5F
|
261.3
|
N/A | N/A |
|
US |
![]() |
Pfizer Inc
NYSE:PFE
|
7.5
|
2%
|
3.8 |
|
EV/EBITDA Forward Multiples
Forward EV/EBITDA multiple is a version of the EV/EBITDA ratio that uses forecasted EBITDA for the EV/EBITDA calculation. 1-Year, 2-Years, and 3-Years forwards use EBITDA forecasts for 1, 2, and 3 years ahead, respectively.